Cargando…
Neurological manifestations and comorbidity associated with COVID-19: an overview
First in 2002, severe acute respiratory syndrome coronavirus (SARS-CoV), second in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV), and now the third in the December 2019, emergence of tremendously pathogenic and large-scale epidemic novel coronavirus (SARS-CoV-2) has brought the worst...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556575/ https://www.ncbi.nlm.nih.gov/pubmed/33052573 http://dx.doi.org/10.1007/s10072-020-04823-6 |
_version_ | 1783594248280473600 |
---|---|
author | Kumar, Mukesh Thakur, Ajit Kumar |
author_facet | Kumar, Mukesh Thakur, Ajit Kumar |
author_sort | Kumar, Mukesh |
collection | PubMed |
description | First in 2002, severe acute respiratory syndrome coronavirus (SARS-CoV), second in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV), and now the third in the December 2019, emergence of tremendously pathogenic and large-scale epidemic novel coronavirus (SARS-CoV-2) has brought the worst conditions into the human inhabitants of the twenty-first century. The SARS-CoV-2 uses the resembling receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly feasts through the respiratory tract. The ACE2 receptor appearances have been also detected upon glial cells and neurons, which makes them a potential target of SARS-CoV-2 disease (COVID-19). Consequently, cells expressing ACE2, apart from lung and cardiovascular tissue, neurons and glial cells may act as targets and are thus vulnerable to SARS-CoV-2 systemic infection as well as its central nervous system (CNS) comorbidities. Investigation of the neurological manifestations of COVID-19 is a step towards better understanding the SARS-CoV-2 infections, inhibiting the additional spread and treating patients affected by this pandemic. In this concern, more clinical examinations for CNS involvement of SARS-CoV-2 are warranted. In this article, we have reviewed the neurological characteristic features of COVID-19 patients, latent neurotropic mechanisms of SARS-CoV-2 involvement in the comorbidity associated with CNS disorders, and neurological manifestations associated with COVID-19. Therefore, in the perspective of COVID-19 pandemic, clinicians and healthcare workers should be aware of a wide spectrum of neurological manifestations associated with COVID-19 along with their signs and symptoms for initial diagnosis and isolation of the patients. |
format | Online Article Text |
id | pubmed-7556575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-75565752020-10-15 Neurological manifestations and comorbidity associated with COVID-19: an overview Kumar, Mukesh Thakur, Ajit Kumar Neurol Sci Covid-19 First in 2002, severe acute respiratory syndrome coronavirus (SARS-CoV), second in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV), and now the third in the December 2019, emergence of tremendously pathogenic and large-scale epidemic novel coronavirus (SARS-CoV-2) has brought the worst conditions into the human inhabitants of the twenty-first century. The SARS-CoV-2 uses the resembling receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly feasts through the respiratory tract. The ACE2 receptor appearances have been also detected upon glial cells and neurons, which makes them a potential target of SARS-CoV-2 disease (COVID-19). Consequently, cells expressing ACE2, apart from lung and cardiovascular tissue, neurons and glial cells may act as targets and are thus vulnerable to SARS-CoV-2 systemic infection as well as its central nervous system (CNS) comorbidities. Investigation of the neurological manifestations of COVID-19 is a step towards better understanding the SARS-CoV-2 infections, inhibiting the additional spread and treating patients affected by this pandemic. In this concern, more clinical examinations for CNS involvement of SARS-CoV-2 are warranted. In this article, we have reviewed the neurological characteristic features of COVID-19 patients, latent neurotropic mechanisms of SARS-CoV-2 involvement in the comorbidity associated with CNS disorders, and neurological manifestations associated with COVID-19. Therefore, in the perspective of COVID-19 pandemic, clinicians and healthcare workers should be aware of a wide spectrum of neurological manifestations associated with COVID-19 along with their signs and symptoms for initial diagnosis and isolation of the patients. Springer International Publishing 2020-10-14 2020 /pmc/articles/PMC7556575/ /pubmed/33052573 http://dx.doi.org/10.1007/s10072-020-04823-6 Text en © Fondazione Società Italiana di Neurologia 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Covid-19 Kumar, Mukesh Thakur, Ajit Kumar Neurological manifestations and comorbidity associated with COVID-19: an overview |
title | Neurological manifestations and comorbidity associated with COVID-19: an overview |
title_full | Neurological manifestations and comorbidity associated with COVID-19: an overview |
title_fullStr | Neurological manifestations and comorbidity associated with COVID-19: an overview |
title_full_unstemmed | Neurological manifestations and comorbidity associated with COVID-19: an overview |
title_short | Neurological manifestations and comorbidity associated with COVID-19: an overview |
title_sort | neurological manifestations and comorbidity associated with covid-19: an overview |
topic | Covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556575/ https://www.ncbi.nlm.nih.gov/pubmed/33052573 http://dx.doi.org/10.1007/s10072-020-04823-6 |
work_keys_str_mv | AT kumarmukesh neurologicalmanifestationsandcomorbidityassociatedwithcovid19anoverview AT thakurajitkumar neurologicalmanifestationsandcomorbidityassociatedwithcovid19anoverview |